Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Henning Willers, M.D.

Title
Institution
Department
Address
Phone
Fax

Overview
I am a laboratory-based clinician-scientist in Radiation Oncology with an interest in basic, translational, and clinical lung cancer research. I spent at least 50% of my time in laboratory based-research and dedicate my clinical time to the management of patients with lung cancer.

The goal of cancer therapy using ionizing radiation and/or chemotherapeutic agents is to selectively kill tumor cells while sparing surrounding normal tissues. In order to achieve such therapeutic gain, pre-existing genetic differences between tumors and normal tissues have to be exploited. To this end, in the Laboratory of Cellular & Molecular Radiation Oncology, we have two main research interests:
1. To detect and characterize altered recombinational DNA repair that may render the affected tumors hypersensitive to DNA damaging agents.
2. To identify and disrupt altered signal transduction pathways, which may sensitize tumors to radiation.
Research in our laboratory is both basic and translational focusing on various tumor entities, including lung and breast cancer, with the long-term goal of contributing to the realization of "personalized" or "individualized" cancer therapy.

The Role of the Tumor Suppressor Gene p53 in DNA Double-Strand Break (DSB) Repair:

DSBs represent the most important type of DNA damage inflicted by radiation or various chemotherapeutic agents. If DSBs are not properly repaired, they can either lead to cell death or produce genetic changes in the surviving cells, which may promote cancer development. Over the past few years, it has become clear that perturbations of DSB repair are a frequent cause of genomic instability in cancer cells. Conversely, these cells may also be more sensitive to DNA damaging agents. Thus, the DSB repair defects that promote carcinogenesis by causing genetic instability may also be the weakness of the tumors that arise in this setting. This concept has been referred to as the "Achilles' Heel of Cancers" and holds great promise for the advancement of cancer treatment in the not-too-distant future. The p53 tumor suppressor is inactivated in the majority of human cancers. In normal cells, p53 suppresses malignant cell transformation through several mechanisms. We recently established a novel role of p53 in the downregulation of homologous recombination (HR), which is a major DSB repair pathway.
A major goal of our current work is to determine how upregulated HR in cells with non-functional p53 contributes to tumor formation and affects cellular sensitivity to DNA damaging agents. We are particularly interested in identifying the upstream proteins that control this effect of p53, including ATR (in collaboration with Lee Zou, Center for Cancer Research). In addition, more recently we described a role of p53 in the control of non-homologous end-joining (NHEJ), which represents another major DSB repair pathway. In the context of these projects, our laboratory has developed a special expertise in the design and application of plasmid substrates that integrate into the genome and allow the study of HR and NHEJ in living cells.

Functional Biomarkers of Radio- and Chemosensitivity:

Many proteins involved in the response to damaged DNA form subnuclear foci that can be detected by immunofluorescence microscopy. These foci represent potentially powerful biomarkers for the activity of a particular repair pathway. We are particularly interested in detecting disruptions of the Fanconi Anemia/BRCA pathway in breast, lung, and other cancer types, which may render the affected tumors hypersensitive to various DNA damaging agents. Ultimately, genotyping and phenotyping of cancers for the integrity of DNA repair pathways will lead to a better prediction of how a given tumor will respond to treatment, and this will allow us to tailor therapy to the individual cancer and patient. We are conducting this research in collaboration with Lisa Kachnic and Carol Rosenberg, Boston University.

Molecularly Targeted Radiation Therapy:

Ionizing radiation not only causes damage to DNA but also affects intra- and inter-cellular signaling pathways in a complex manner. Many of these alterations constitute cytoprotective responses that help cells to survive radiation exposure. In collaboration with Jeff Settleman, Center for Molecular Therapeutics in the Center for Cancer Research, we are seeking to identify signaling alterations in lung cancers that can be targeted in order to overcome the resistance of these tumors to radiation.

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. U01CA220714 (WILLERS, HENNING) Jul 1, 2018 - Jun 30, 2023
    NIH/NCI
    High-Throughput Screening and Validation of Molecular Targeted Chemoradiosensitizers
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Lebow ES, Hwang WL, Zieminski S, Wang Y, Niemierko A, Mehan WA, Oh KS, Khandekar M, Willers H, Shih HA. Early experience with hippocampal avoidance whole brain radiation therapy and simultaneous integrated boost for brain metastases. J Neurooncol. 2020 May; 148(1):81-88. PMID: 32307637.
    Citations:    
  2. Gainor JF, Stevens SE, Willers H, Shih HA, Heist RS. Intracranial Activity of Gefitinib and Capmatinib in a Patient with Previously Treated Non-Small Cell Lung Cancer Harboring a Concurrent EGFR Mutation and MET Amplification. J Thorac Oncol. 2020 01; 15(1):e8-e10. PMID: 31864558.
    Citations:    
  3. Roberts TJ, Lennes IT, Hawari S, Sequist LV, Park ER, Willers H, Frank A, Gaissert H, Shepard JA, Ryan D. Integrated, Multidisciplinary Management of Pulmonary Nodules Can Streamline Care and Improve Adherence to Recommendations. Oncologist. 2020 May; 25(5):431-437. PMID: 31876321.
    Citations:    
  4. McNamara A, Willers H, Paganetti H. Modelling variable proton relative biological effectiveness for treatment planning. Br J Radiol. 2020 Mar; 93(1107):20190334. PMID: 31738081.
    Citations:    
  5. Willers H, Keane FK, Kamran SC. Toward a New Framework for Clinical Radiation Biology. Hematol Oncol Clin North Am. 2019 12; 33(6):929-945. PMID: 31668212.
    Citations:    
  6. Gurtner K, Kryzmien Z, Koi L, Wang M, Benes CH, Hering S, Willers H, Baumann M, Krause M. Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo. Int J Cancer. 2020 Jul 15; 147(2):472-477. PMID: 31359406.
    Citations:    
  7. Kamran SC, Lennerz JK, Margolis CA, Liu D, Reardon B, Wankowicz SA, Van Seventer EE, Tracy A, Wo JY, Carter SL, Willers H, Corcoran RB, Hong TS, Van Allen EM. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. Clin Cancer Res. 2019 09 15; 25(18):5561-5571. PMID: 31253631.
    Citations:    
  8. Marcar L, Bardhan K, Gheorghiu L, Dinkelborg P, Pfäffle H, Liu Q, Wang M, Piotrowska Z, Sequist LV, Borgmann K, Settleman JE, Engelman JA, Hata AN, Willers H. Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity. Cell Rep. 2019 06 18; 27(12):3422-3432.e4. PMID: 31216465.
    Citations:    
  9. Sebastian N, Wu T, Driscoll E, Willers H, Kelly S, Musunuru HB, Mo X, Tan Y, Bazan J, Haglund K, Xu-Welliver M, Baschnagel AM, Ju A, Keane F, Williams TM. Pre-treatment serum bicarbonate predicts for primary tumor control after stereotactic body radiation therapy in patients with localized non-small cell lung cancer. Radiother Oncol. 2019 11; 140:26-33. PMID: 31176206.
    Citations:    
  10. Grassberger C, McClatchy D, Geng C, Kamran SC, Fintelmann F, Maruvka YE, Piotrowska Z, Willers H, Sequist LV, Hata AN, Paganetti H. Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies. Cancer Res. 2019 07 15; 79(14):3776-3788. PMID: 31113818.
    Citations:    
  11. Li Y, Dykstra M, Best TD, Pursley J, Chopra N, Keane FK, Khandekar MJ, Sharp GC, Paganetti H, Willers H, Fintelmann FJ, Grassberger C. Differential inflammatory response dynamics in normal lung following stereotactic body radiation therapy with protons versus photons. Radiother Oncol. 2019 07; 136:169-175. PMID: 31015121.
    Citations:    
  12. Sebastian N, Wu T, Bazan J, Driscoll E, Willers H, Yegya-Raman N, Bond L, Dwivedi A, Mo X, Tan Y, Xu-Welliver M, Haglund K, Jabbour SK, Keane FK, Williams TM. Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy. Radiother Oncol. 2019 05; 134:151-157. PMID: 31005209.
    Citations:    
  13. Paganetti H, Blakely E, Carabe-Fernandez A, Carlson DJ, Das IJ, Dong L, Grosshans D, Held KD, Mohan R, Moiseenko V, Niemierko A, Stewart RD, Willers H. Report of the AAPM TG-256 on the relative biological effectiveness of proton beams in radiation therapy. Med Phys. 2019 Mar; 46(3):e53-e78. PMID: 30661238.
    Citations:    Fields:    
  14. Dinkelborg PH, Wang M, Gheorghiu L, Gurski JM, Hong TS, Benes CH, Juric D, Jimenez RB, Borgmann K, Willers H. A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types. Breast Cancer Res Treat. 2019 Apr; 174(3):605-613. PMID: 30607635.
    Citations:    Fields:    
  15. Aktar R, Dietrich A, Tillner F, Kotb S, Löck S, Willers H, Baumann M, Krause M, Bütof R. Pre-clinical imaging for establishment and comparison of orthotopic non-small cell lung carcinoma: in search for models reflecting clinical scenarios. Br J Radiol. 2019 Mar; 92(1095):20180539. PMID: 30215546.
    Citations:    Fields:    
  16. Willers H, Wang M, Benes CH. TP53 mutation status: emerging biomarker for precision radiation medicine? Oncoscience. 2018 Sep; 5(9-10):258-259. PMID: 30460326.
    Citations:    
  17. Willers H, Allen A, Grosshans D, McMahon SJ, von Neubeck C, Wiese C, Vikram B. Toward A variable RBE for proton beam therapy. Radiother Oncol. 2018 07; 128(1):68-75. PMID: 29910006.
    Citations:    Fields:    Translation:HumansCells
  18. Bristow RG, Alexander B, Baumann M, Bratman SV, Brown JM, Camphausen K, Choyke P, Citrin D, Contessa JN, Dicker A, Kirsch DG, Krause M, Le QT, Milosevic M, Morris ZS, Sarkaria JN, Sondel PM, Tran PT, Wilson GD, Willers H, Wong RKS, Harari PM. Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. Lancet Oncol. 2018 05; 19(5):e240-e251. PMID: 29726389.
    Citations: 2     Fields:    
  19. Khandekar MJ, Piotrowska Z, Willers H, Sequist LV. Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers. Oncologist. 2018 09; 23(9):1054-1062. PMID: 29703765.
    Citations:    Fields:    
  20. Kirsch DG, Diehn M, Kesarwala AH, Maity A, Morgan MA, Schwarz JK, Bristow R, Demaria S, Eke I, Griffin RJ, Haas-Kogan D, Higgins GS, Kimmelman AC, Kimple RJ, Lombaert IM, Ma L, Marples B, Pajonk F, Park CC, Schaue D, Tran PT, Bernhard EJ. The Future of Radiobiology. J Natl Cancer Inst. 2018 04 01; 110(4):329-340. PMID: 29126306.
    Citations:    Fields:    
  21. Liu Q, Gheorghiu L, Drumm M, Clayman R, Eidelman A, Wszolek MF, Olumi A, Feldman A, Wang M, Marcar L, Citrin DE, Wu CL, Benes CH, Efstathiou JA, Willers H. PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53. Oncogene. 2018 05; 37(21):2793-2805. PMID: 29511347.
    Citations: 1     Fields:    
  22. Hong TS, Wo JY, Borger DR, Yeap BY, McDonnell EI, Willers H, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Tanguturi S, Goyal L, Murphy JE, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Tanabe KK, Ferrone CR, Ryan DP, Iafrate AJ, DeLaney TF, Zhu AX. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. J Natl Cancer Inst. 2017 09 01; 109(9). PMID: 28954285.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  23. Hall WA, Bergom C, Thompson RF, Baschnagel AM, Vijayakumar S, Willers H, Li XA, Schultz CJ, Wilson GD, West CML, Capala J, Coleman CN, Torres-Roca JF, Weidhaas J, Feng FY. Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference. Int J Radiat Oncol Biol Phys. 2018 06 01; 101(2):274-284. PMID: 28964588.
    Citations: 4     Fields:    
  24. Wang M, Han J, Marcar L, Black J, Liu Q, Li X, Nagulapalli K, Sequist LV, Mak RH, Benes CH, Hong TS, Gurtner K, Krause M, Baumann M, Kang JX, Whetstine JR, Willers H. Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. Cancer Res. 2017 04 15; 77(8):2018-2028. PMID: 28202526.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  25. Verma V, Simone CB, Allen PK, Gajjar SR, Shah C, Zhen W, Harkenrider MM, Hallemeier CL, Jabbour SK, Matthiesen CL, Braunstein SE, Lee P, Dilling TJ, Allen BG, Nichols EM, Attia A, Zeng J, Biswas T, Paximadis P, Wang F, Walker JM, Stahl JM, Daly ME, Decker RH, Hales RK, Willers H, Videtic GM, Mehta MP, Lin SH. Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):362-371. PMID: 28011047.
    Citations: 8     Fields:    Translation:Humans
  26. Campo M, Al-Halabi H, Khandekar M, Shaw AT, Sequist LV, Willers H. Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer. Oncologist. 2016 08; 21(8):964-73. PMID: 27354669.
    Citations: 2     Fields:    Translation:Humans
  27. Underwood T, Grassberger C, Willers H, MacDonald S, Jimenez R, Paganetti H. WE-FG-202-03: Quantitative CT-Based Analysis to Assess Lung Injury Following Proton Radiotherapy. Med Phys. 2016 Jun; 43(6):3827. PMID: 28048337.
    Citations:    
  28. Coleman CN, Higgins GS, Brown JM, Baumann M, Kirsch DG, Willers H, Prasanna PG, Dewhirst MW, Bernhard EJ, Ahmed MM. Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials. Clin Cancer Res. 2016 07 01; 22(13):3138-47. PMID: 27154913.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  29. Held KD, Kawamura H, Kaminuma T, Paz AE, Yoshida Y, Liu Q, Willers H, Takahashi A. Effects of Charged Particles on Human Tumor Cells. Front Oncol. 2016; 6:23. PMID: 26904502.
    Citations: 6     
  30. Liu Q, Underwood TSA, Kung J, Wang M, Lu HM, Paganetti H, Held KD, Hong TS, Efstathiou JA, Willers H. Disruption of SLX4-MUS81 Function Increases the Relative Biological Effectiveness of Proton Radiation. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):78-85. PMID: 27084631.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  31. Kamran SC, Mueller BS, Paetzold P, Dunlap J, Niemierko A, Bortfeld T, Willers H, Craft D. Multi-criteria optimization achieves superior normal tissue sparing in a planning study of intensity-modulated radiation therapy for RTOG 1308-eligible non-small cell lung cancer patients. Radiother Oncol. 2016 Mar; 118(3):515-20. PMID: 26830694.
    Citations: 2     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  32. Al-Halabi H, Sayegh K, Digamurthy SR, Niemierko A, Piotrowska Z, Willers H, Sequist LV. Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy. J Thorac Oncol. 2015 Nov; 10(11):1601-7. PMID: 26313684.
    Citations: 5     Fields:    Translation:Humans
  33. Grassberger C, Sharp G, Fintelmann F, Paganetti H, Willers H. SU-E-J-247: Time Evolution of Radiation-Induced Lung Injury After Stereotactic Proton Therapy. Med Phys. 2015 Jun; 42(6):3323. PMID: 26127638.
    Citations:    
  34. Willers H, Gheorghiu L, Liu Q, Efstathiou JA, Wirth LJ, Krause M, von Neubeck C. DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity. Semin Radiat Oncol. 2015 Oct; 25(4):237-50. PMID: 26384272.
    Citations: 13     Fields:    Translation:Humans
  35. Willers H, Stinchcombe TE, Barriger RB, Chetty IJ, Ginsburg ME, Kestin LL, Kumar S, Loo BW, Movsas B, Rimner A, Rosenzweig KE, Videtic GM, Chang JY. ACR Appropriateness Criteria(®) induction and adjuvant therapy for N2 non-small-cell lung cancer. Am J Clin Oncol. 2015 Apr; 38(2):197-205. PMID: 25803563.
    Citations: 4     Fields:    Translation:Humans
  36. Liu Q, Ghosh P, Magpayo N, Testa M, Tang S, Gheorghiu L, Biggs P, Paganetti H, Efstathiou JA, Lu HM, Held KD, Willers H. Lung cancer cell line screen links fanconi anemia/BRCA pathway defects to increased relative biological effectiveness of proton radiation. Int J Radiat Oncol Biol Phys. 2015 Apr 01; 91(5):1081-9. PMID: 25832698.
    Citations: 13     Fields:    Translation:HumansCells
  37. Al-Halabi H, Paetzold P, Sharp GC, Olsen C, Willers H. A Contralateral Esophagus-Sparing Technique to Limit Severe Esophagitis Associated With Concurrent High-Dose Radiation and Chemotherapy in Patients With Thoracic Malignancies. Int J Radiat Oncol Biol Phys. 2015 Jul 15; 92(4):803-10. PMID: 26104934.
    Citations: 4     Fields:    Translation:HumansPHPublic Health
  38. Liu Q, Wang M, Kern AM, Khaled S, Han J, Yeap BY, Hong TS, Settleman J, Benes CH, Held KD, Efstathiou JA, Willers H. Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers. Mol Cancer Res. 2015 Apr; 13(4):713-20. PMID: 25667133.
    Citations: 5     Fields:    Translation:HumansCells
  39. Willers H, Hong TS. Towards an integrated understanding of epidermal growth factor receptor biology for radiation therapy: integrins enter. J Natl Cancer Inst. 2015 Feb; 107(2). PMID: 25663686.
    Citations:    Fields:    Translation:HumansAnimals
  40. Xiong X, Du Z, Wang Y, Feng Z, Fan P, Yan C, Willers H, Zhang J. 53BP1 promotes microhomology-mediated end-joining in G1-phase cells. Nucleic Acids Res. 2015 Feb 18; 43(3):1659-70. PMID: 25586219.
    Citations: 8     Fields:    Translation:HumansCells
  41. Chang JY, Kestin LL, Barriger RB, Chetty IJ, Ginsburg ME, Kumar S, Loo BW, Movsas B, Rimner A, Rosenzweig KE, Stinchcombe TE, Videtic GM, Willers H. ACR Appropriateness Criteria® nonsurgical treatment for locally advanced non-small-cell lung cancer: good performance status/definitive intent. Oncology (Williston Park). 2014 Aug 15; 28(8):706-10, 712, 714 passim. PMID: 25140629.
    Citations: 13     Fields:    Translation:Humans
  42. Mak KS, Gainor JF, Niemierko A, Oh KS, Willers H, Choi NC, Loeffler JS, Sequist LV, Shaw AT, Shih HA. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Neuro Oncol. 2015 Feb; 17(2):296-302. PMID: 25053852.
    Citations: 15     Fields:    Translation:Humans
  43. Videtic GM, Chang JY, Chetty IJ, Ginsburg ME, Kestin LL, Kong FM, Lally BE, Loo BW, Movsas B, Stinchcombe TE, Willers H, Rosenzweig KE. ACR appropriateness Criteria® early-stage non-small-cell lung cancer. Am J Clin Oncol. 2014 Apr; 37(2):201-7. PMID: 25180631.
    Citations: 1     Fields:    Translation:Humans
  44. Wang M, Kern AM, Hülskötter M, Greninger P, Singh A, Pan Y, Chowdhury D, Krause M, Baumann M, Benes CH, Efstathiou JA, Settleman J, Willers H. EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation. Cancer Res. 2014 May 15; 74(10):2825-34. PMID: 24648348.
    Citations: 15     Fields:    Translation:HumansAnimalsCells
  45. Seco J, Gu G, Marcelos T, Kooy H, Willers H. Proton arc reduces range uncertainty effects and improves conformality compared with photon volumetric modulated arc therapy in stereotactic body radiation therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Sep 01; 87(1):188-94. PMID: 23920395.
    Citations: 8     Fields:    Translation:HumansPHPublic Health
  46. Pfäffle HN, Wang M, Gheorghiu L, Ferraiolo N, Greninger P, Borgmann K, Settleman J, Benes CH, Sequist LV, Zou L, Willers H. EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity. Cancer Res. 2013 Oct 15; 73(20):6254-63. PMID: 23966292.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  47. Rosenzweig KE, Chang JY, Chetty IJ, Decker RH, Ginsburg ME, Kestin LL, Kong FM, Lally BE, Langer CJ, Movsas B, Videtic GM, Willers H. ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent. J Am Coll Radiol. 2013 Sep; 10(9):654-64. PMID: 23890874.
    Citations: 4     Fields:    Translation:Humans
  48. Willers H, Azzoli CG, Santivasi WL, Xia F. Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer. Cancer J. 2013 May-Jun; 19(3):200-7. PMID: 23708066.
    Citations: 29     Fields:    Translation:HumansAnimalsCells
  49. Kong FM, Lally BE, Chang JY, Chetty IJ, Decker RH, Ginsburg ME, Kestin LL, Langer CJ, Movsas B, Videtic GM, Willers H, Rosenzweig KE. ACR Appropriateness Criteria® radiation therapy for small-cell lung cancer. Am J Clin Oncol. 2013 Apr; 36(2):206-13. PMID: 23511336.
    Citations: 2     Fields:    Translation:Humans
  50. Birkelbach M, Ferraiolo N, Gheorghiu L, Pfäffle HN, Daly B, Ebright MI, Spencer C, O'Hara C, Whetstine JR, Benes CH, Sequist LV, Zou L, Dahm-Daphi J, Kachnic LA, Willers H. Detection of impaired homologous recombination repair in NSCLC cells and tissues. J Thorac Oncol. 2013 Mar; 8(3):279-86. PMID: 23399959.
    Citations: 13     Fields:    Translation:HumansCells
  51. Grassberger C, Dowdell S, Lomax A, Sharp G, Shackleford J, Choi N, Willers H, Paganetti H. Motion interplay as a function of patient parameters and spot size in spot scanning proton therapy for lung cancer. Int J Radiat Oncol Biol Phys. 2013 Jun 01; 86(2):380-6. PMID: 23462423.
    Citations: 24     Fields:    Translation:Humans
  52. Goldberg SB, Willers H, Heist RS. Multidisciplinary management of small cell lung cancer. Surg Oncol Clin N Am. 2013 Apr; 22(2):329-43. PMID: 23453338.
    Citations: 6     Fields:    Translation:Humans
  53. Westover KD, Seco J, Adams JA, Lanuti M, Choi NC, Engelsman M, Willers H. Proton SBRT for medically inoperable stage I NSCLC. J Thorac Oncol. 2012 Jun; 7(6):1021-5. PMID: 22551902.
    Citations: 14     Fields:    Translation:Humans
  54. Lanuti M, Sharma A, Willers H, Digumarthy SR, Mathisen DJ, Shepard JA. Radiofrequency ablation for stage I non-small cell lung cancer: management of locoregional recurrence. Ann Thorac Surg. 2012 Mar; 93(3):921-7; discussion 927-88. PMID: 22296982.
    Citations: 23     Fields:    Translation:Humans
  55. Mak RH, Alexander BM, Asomaning K, Heist RS, Liu CY, Su L, Zhai R, Ancukiewicz M, Napolitano B, Niemierko A, Willers H, Choi NC, Christiani DC. A single-nucleotide polymorphism in the methylene tetrahydrofolate reductase (MTHFR) gene is associated with risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy. Cancer. 2012 Jul 15; 118(14):3654-65. PMID: 22144047.
    Citations: 9     Fields:    Translation:Humans
  56. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, Tammireddy S, Morrissey L, Muzikansky A, Goldberg SB, Gainor J, Channick CL, Wain JC, Gaissert H, Donahue DM, Muniappan A, Wright C, Willers H, Mathisen DJ, Choi NC, Baselga J, Lynch TJ, Ellisen LW, Mino-Kenudson M, Lanuti M, Borger DR, Iafrate AJ, Engelman JA, Dias-Santagata D. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011 Dec; 22(12):2616-2624. PMID: 22071650.
    Citations: 105     Fields:    Translation:Humans
  57. Seco J, Panahandeh HR, Westover K, Adams J, Willers H. Treatment of non-small cell lung cancer patients with proton beam-based stereotactic body radiotherapy: dosimetric comparison with photon plans highlights importance of range uncertainty. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):354-61. PMID: 21985941.
    Citations: 15     Fields:    Translation:HumansPHPublic Health
  58. Chiba N, Comaills V, Shiotani B, Takahashi F, Shimada T, Tajima K, Winokur D, Hayashida T, Willers H, Brachtel E, Vivanco MD, Haber DA, Zou L, Maheswaran S. Homeobox B9 induces epithelial-to-mesenchymal transition-associated radioresistance by accelerating DNA damage responses. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2760-5. PMID: 21930940.
    Citations: 24     Fields:    Translation:HumansCells
  59. Wang M, Morsbach F, Sander D, Gheorghiu L, Nanda A, Benes C, Kriegs M, Krause M, Dikomey E, Baumann M, Dahm-Daphi J, Settleman J, Willers H. EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Res. 2011 Oct 01; 71(19):6261-9. PMID: 21852385.
    Citations: 37     Fields:    Translation:HumansCells
  60. Sirbu BM, Lachmayer SJ, Wülfing V, Marten LM, Clarkson KE, Lee LW, Gheorghiu L, Zou L, Powell SN, Dahm-Daphi J, Willers H. ATR-p53 restricts homologous recombination in response to replicative stress but does not limit DNA interstrand crosslink repair in lung cancer cells. PLoS One. 2011; 6(8):e23053. PMID: 21857991.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  61. Kachnic LA, Li L, Fournier L, Ferraiolo N, Dahm-Daphi J, Borgmann K, Willers H. FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons. Cancer Lett. 2011 Jun 01; 305(1):86-93. PMID: 21414716.
    Citations: 6     Fields:    Translation:HumansCells
  62. Mak RH, Doran E, Muzikansky A, Kang J, Neal JW, Baldini EH, Choi NC, Willers H, Jackman DM, Sequist LV. Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC. Oncologist. 2011; 16(6):886-95. PMID: 21632451.
    Citations: 17     Fields:    Translation:Humans
  63. Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, Lynch TJ, Sequist LV. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol. 2010 Nov; 12(11):1193-9. PMID: 20627894.
    Citations: 96     Fields:    Translation:Humans
  64. Kachnic LA, Li L, Fournier L, Willers H. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments. Cancer Lett. 2010 Jun 01; 292(1):73-9. PMID: 20034732.
    Citations: 9     Fields:    Translation:HumansCells
  65. Zhuang J, Jiang G, Willers H, Xia F. Exonuclease function of human Mre11 promotes deletional nonhomologous end joining. J Biol Chem. 2009 Oct 30; 284(44):30565-73. PMID: 19744924.
    Citations: 30     Fields:    Translation:HumansCells
  66. Willers H, Taghian AG, Luo CM, Treszezamsky A, Sgroi DC, Powell SN. Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol Cancer Res. 2009 Aug; 7(8):1304-9. PMID: 19671671.
    Citations: 45     Fields:    Translation:HumansCells
  67. Kuhnert VM, Kachnic LA, Li L, Purschke M, Gheorghiu L, Lee R, Held KD, Willers H. FANCD2-deficient human fibroblasts are hypersensitive to ionising radiation at oxygen concentrations of 0% and 3% but not under normoxic conditions. Int J Radiat Biol. 2009 Jun; 85(6):523-31. PMID: 19466639.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  68. Nanda A, Dias-Santagata DC, Stubbs H, O'Hara CJ, Zaner KS, Lynch TJ, Willers H. Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer. Clin Lung Cancer. 2008 Sep; 9(5):285-7. PMID: 18824451.
    Citations: 4     Fields:    Translation:Humans
  69. Shi W, Ma Z, Willers H, Akhtar K, Scott SP, Zhang J, Powell S, Zhang J. Disassembly of MDC1 foci is controlled by ubiquitin-proteasome-dependent degradation. J Biol Chem. 2008 Nov 14; 283(46):31608-16. PMID: 18757370.
    Citations: 26     Fields:    Translation:HumansCells
  70. Mansour WY, Schumacher S, Rosskopf R, Rhein T, Schmidt-Petersen F, Gatzemeier F, Haag F, Borgmann K, Willers H, Dahm-Daphi J. Hierarchy of nonhomologous end-joining, single-strand annealing and gene conversion at site-directed DNA double-strand breaks. Nucleic Acids Res. 2008 Jul; 36(12):4088-98. PMID: 18539610.
    Citations: 63     Fields:    Translation:AnimalsCells
  71. Schulte-Uentrop L, El-Awady RA, Schliecker L, Willers H, Dahm-Daphi J. Distinct roles of XRCC4 and Ku80 in non-homologous end-joining of endonuclease- and ionizing radiation-induced DNA double-strand breaks. Nucleic Acids Res. 2008 May; 36(8):2561-9. PMID: 18332040.
    Citations: 36     Fields:    Translation:AnimalsCells
  72. Willers H, Kachnic LA, Luo CM, Li L, Purschke M, Borgmann K, Held KD, Powell SN. Biomarkers and mechanisms of FANCD2 function. J Biomed Biotechnol. 2008; 2008:821529. PMID: 18483568.
    Citations: 9     Fields:    Translation:HumansCells
  73. Willers H, Husson J, Lee LW, Hubbe P, Gazemeier F, Powell SN, Dahm-Daphi J. Distinct mechanisms of nonhomologous end joining in the repair of site-directed chromosomal breaks with noncomplementary and complementary ends. Radiat Res. 2006 Oct; 166(4):567-74. PMID: 17007549.
    Citations: 15     Fields:    Translation:AnimalsCells
  74. Zhuang J, Zhang J, Willers H, Wang H, Chung JH, van Gent DC, Hallahan DE, Powell SN, Xia F. Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining. Cancer Res. 2006 Feb 01; 66(3):1401-8. PMID: 16452195.
    Citations: 45     Fields:    Translation:HumansCells
  75. Willers H, Held KD. Introduction to clinical radiation biology. Hematol Oncol Clin North Am. 2006 Feb; 20(1):1-24. PMID: 16580554.
    Citations: 13     Fields:    Translation:Humans
  76. H.Willers, J. Dahm-Daphi, L. Li, C. M. Luo, S. N. Powell, L. A. Kachnic . Disruption of the Fanconi Anemia D2 gene causes cellular hypersensitivity to DNA topoisomerase II inhibitors. In press. 2006.
  77. H. Willers, C. M. Luo, A. Treszezamsky, A. G. Taghian, S. N. Powell. Monitoring The Cellular Response To Radiation-Induced DNA Damage In Human Breast Cancer Biopsies Ex-Vivo. In Press. 2006.
  78. H. Willers, C. M. Luo, M. Purschke, K. D. Held, S. N. Powell. . A dual role of the Fanconi Anemia D2 protein in the cellular response to DNA crosslinks and reactive oxygen species. In press. 2006.
  79. Dahm-Daphi J, Hubbe P, Horvath F, El-Awady RA, Bouffard KE, Powell SN, Willers H. Nonhomologous end-joining of site-specific but not of radiation-induced DNA double-strand breaks is reduced in the presence of wild-type p53. Oncogene. 2005 Mar 03; 24(10):1663-72. PMID: 15688024.
    Citations: 23     Fields:    Translation:AnimalsCells
  80. H. Willers, Z. Feng, K. E. Bouffard, S. N. Powell. Upregulated homologous recombination upon loss of p53 function dose not improve cell survival following treatment with DNA damaging agents. International Journal of Radiation Oncology Biology Physics. 47th Annual Meeting of ASTRO. 2005.
  81. Romanova LY, Willers H, Blagosklonny MV, Powell SN. The interaction of p53 with replication protein A mediates suppression of homologous recombination. Oncogene. 2004 Dec 02; 23(56):9025-33. PMID: 15489903.
    Citations: 31     Fields:    Translation:HumansCells
  82. Willers H, DeLaney TF. Dermatofibrosarcoma protuberans: treatment options. Current Opinion in Orthopaedics. 2004; 15(6):447-451.
  83. Willers H, Dahm-Daphi J, Powell SN. Repair of radiation damage to DNA. Br J Cancer. 2004 Apr 05; 90(7):1297-301. PMID: 15054444.
    Citations: 36     Fields:    Translation:HumansAnimalsCells
  84. Zhang J, Willers H, Feng Z, Ghosh JC, Kim S, Weaver DT, Chung JH, Powell SN, Xia F. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol. 2004 Jan; 24(2):708-18. PMID: 14701743.
    Citations: 109     Fields:    Translation:HumansCells
  85. Veeken AH, de Wilde V, Willers HC, Hamelers HV. Odour abatement in the integrated reactor concept for simultaneous treatment of liquid and solid pig manure fractions. Water Sci Technol. 2004; 50(4):327-34. PMID: 15484777.
    Citations: 1     Fields:    Translation:AnimalsPHPublic Health
  86. H. Willers, S. N. Powell, J. Dahm-Daphi. Genetic analysis of chromosomal double-strand break repair by non-homologous end-joining. International Journal of Radiation Oncology Biology Physics. 46th Annual Meeting of ASTRO. 2004; 60:S345.
  87. H. Willers, L. Romanova, J. Dahm-Daphi, S. N. Powell. Regulation of homologous recombination during DNA replication: Defining the role of p53. AACR Special Conference Proceedings. 2004; B22.
  88. Suit HD, Willers H. Comment on "Tumor response to radiotherapy regulated by endothelial cell apoptosis" (I). Science. 2003 Dec 12; 302(5652):1894; author reply 1894. PMID: 14671277.
    Citations: 7     Fields:    Translation:Animals
  89. H. Willers, S. N. Powell, J. Dahm-Daphi. p53 regulates the repair of DNA double-strand breaks by both homologous and non-homologous recombination. Final Program and Book of Abstracts. 12th International Congress of Radiation Research. 2003; 315.
  90. Powell SN, Willers H, Xia F. BRCA2 keeps Rad51 in line. High-fidelity homologous recombination prevents breast and ovarian cancer? Mol Cell. 2002 Dec; 10(6):1262-3. PMID: 12504001.
    Citations: 13     Fields:    Translation:Humans
  91. H. Willers, L. Romanova, C. Krivacek, J. Dahm-Daphi, S. N. Powell, F. Xia. Regulation of homologous DNA recombination by the tumor suppressor gene p53: analysis of mechanisms. Strahlentherapie und Onkologie. 6th German Conference for Radiooncology, Radiobiology and Medical Physics. 2002; 178:17.
  92. Willers H, Xia F, Powell SN. Recombinational DNA Repair in Cancer and Normal Cells: The Challenge of Functional Analysis. J Biomed Biotechnol. 2002; 2(2):86-93. PMID: 12488588.
    Citations: 3     Fields:    
  93. H. Willers, T. Phalen, J. Zhang, J. Dahm-Daphi, F. Xia, S. N. Powell. Repair of DNA double-strand breaks by XRCC4-dependent and -independent non-homologous end-joining. International Journal of Radiation Oncology Biology Physics. 44th Annual Meeting of ASTRO. 2002; 54:51.
  94. Willers H, McCarthy EE, Hubbe P, Dahm-Daphi J, Powell SN. Homologous recombination in extrachromosomal plasmid substrates is not suppressed by p53. Carcinogenesis. 2001 Nov; 22(11):1757-63. PMID: 11698336.
    Citations: 12     Fields:    Translation:AnimalsCells
  95. Xia F, Taghian DG, DeFrank JS, Zeng ZC, Willers H, Iliakis G, Powell SN. Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc Natl Acad Sci U S A. 2001 Jul 17; 98(15):8644-9. PMID: 11447276.
    Citations: 65     Fields:    Translation:HumansCells
  96. Willers H, McCarthy EE, Alberti W, Dahm-Daphi J, Powell SN. Loss of wild-type p53 function is responsible for upregulated homologous recombination in immortal rodent fibroblasts. Int J Radiat Biol. 2000 Aug; 76(8):1055-62. PMID: 10947118.
    Citations: 9     Fields:    Translation:AnimalsCells
  97. Willers H, McCarthy EE, Wu B, Wunsch H, Tang W, Taghian DG, Xia F, Powell SN. Dissociation of p53-mediated suppression of homologous recombination from G1/S cell cycle checkpoint control. Oncogene. 2000 Feb 03; 19(5):632-9. PMID: 10698508.
    Citations: 26     Fields:    Translation:HumansAnimalsCells
  98. Tang W, Willers H, Powell SN. p53 directly enhances rejoining of DNA double-strand breaks with cohesive ends in gamma-irradiated mouse fibroblasts. Cancer Res. 1999 Jun 01; 59(11):2562-5. PMID: 10363973.
    Citations: 18     Fields:    Translation:AnimalsCells
  99. H. Willers, E. McCarthy, B. Wu, H. Wunsch, W. Tang, F. Xia, S. N. Powell . p53 tumor mutants vary in their ability to suppress homologous recombination. Congress Abstracts. 11th International Congress of Radiation Research. 1999; 1:178.
  100. Willers H, Heilmann HP, Beck-Bornholdt HP. [One hundred years of radiotherapy. Historical origins and development of fractionated irradiation in German speaking countries]. Strahlenther Onkol. 1998 Feb; 174(2):53-63. PMID: 9487366.
    Citations:    Fields:    Translation:Humans
  101. Willers H, Würschmidt F, Bünemann H, Heilmann HP. High-dose radiation therapy alone for inoperable non-small cell lung cancer--experience with prolonged overall treatment times. Acta Oncol. 1998; 37(1):101-5. PMID: 9572662.
    Citations: 2     Fields:    Translation:Humans
  102. Willers H, Liertz-Petersen C, Dubben HH, Beck-Bornholdt HP. Outcome of hyperfractionated radiation therapy in randomized clinical trials. Int J Radiat Oncol Biol Phys. 1998 Jan 01; 40(1):257-9. PMID: 9422584.
    Citations: 1     Fields:    Translation:Humans
  103. H. Willers, R. M. Douglas, W. Tang, S. N. Powell. Homologous recombination is suppressed by p53 for intra-chromosomal substrates, but not in extra-chromosomal substrates. Program Abstracts. 46th Annual Meeting of the Radiation Research Society. 1998; 138.
  104. Beck-Bornholdt HP, Dubben HH, Willers H. [Proliferation rate and radiosensitivity. Bergonié's and Tribondeau's error]. Strahlenther Onkol. 1997 Jun; 173(6):335-7. PMID: 9235641.
    Citations: 2     Fields:    Translation:HumansPHPublic Health
  105. Beck-Bornholdt HP, Dubben HH, Liertz-Petersen C, Willers H. Hyperfractionation: where do we stand? Radiother Oncol. 1997 Apr; 43(1):1-21. PMID: 9165132.
    Citations: 6     Fields:    Translation:Humans
  106. Willers H, Prosch B, Beck-Bornholdt HP. Impact of the interfraction interval on clonogenic cell survival in split-dose irradiation of R1H rhabdomyosarcoma of the rat in vitro. Radiother Oncol. 1997 Apr; 43(1):93-6. PMID: 9165143.
    Citations:    Fields:    Translation:AnimalsCells
  107. Willers H, Hug EB, Spiro IJ, Efird JT, Rosenberg AE, Wang CC. [Soft tissue sarcoma of the head and neck area in adults. Outcome of combined surgery and irradiation and radiotherapy alone]. Strahlenther Onkol. 1997 Mar; 173(3):131-5. PMID: 9122852.
    Citations: 3     Fields:    Translation:Humans
  108. Willers H, Würschmidt F, Janik I, Bünemann H, Heilmann HP. [Combined breast-preserving surgery, chemotherapy and radiotherapy in the treatment of breast carcinoma. Effect of the interval between surgery and the beginning of radiotherapy]. Strahlenther Onkol. 1997 Mar; 173(3):148-54. PMID: 9122856.
    Citations: 2     Fields:    Translation:Humans
  109. H. Willers, F. Wurschmidt, I. Janik, H. Bunemann, H.-P. Heilmann. [Timing of postoperative chemotherapy and radiation in breast cancer treatment: Local versus systemic control]. Strahlentherapie und Onkologie. 3rd German Conference for Radiooncology, Radiobiology and Medical Physics. 1997; 173:544.
  110. H. Willers, F. Wurschmidt, H. Bunemann, H.-P. Heilmann . The impact of overall treatment time and selection bias on long-term survival after radiotherapy alone for non-small cell lung cancer (NSCLC). Radiotherapy & Oncology. 15th Annual Meeting of ESTRO. 1996; 40:S61.
  111. Willers H, Beck-Bornholdt HP. [Historical experiences in trying different overall treatment times in x-ray therapy of malignant head and neck tumors in the 1920s and 1930s]. Strahlenther Onkol. 1996 Sep; 172(9):512-5. PMID: 8928059.
    Citations:    Fields:    Translation:Humans
  112. Willers H, Beck-Bornholdt HP. Origins of radiotherapy and radiobiology: separation of the influence of dose per fraction and overall treatment time on normal tissue damage by Reisner and Miescher in the 1930s. Radiother Oncol. 1996 Feb; 38(2):171-3. PMID: 8966230.
    Citations: 1     Fields:    Translation:HumansAnimalsPHPublic Health
  113. H. Willers, F. Wurschmidt, I. Janik, H. Bunemann, H.-P. Heilmann. Combined conservative surgery, chemotherapy and radiation therapy in treatment of the breast cancer patient: the influence of the interval between surgery and start of irradiation. International Journal of Radiation Oncology Biology Physics. 38th Annual Meeting of ASTRO. 1996; 36:280.
  114. Willers H, Hug EB, Spiro IJ, Efird JT, Rosenberg AE, Wang CC. Adult soft tissue sarcomas of the head and neck treated by radiation and surgery or radiation alone: patterns of failure and prognostic factors. Int J Radiat Oncol Biol Phys. 1995 Oct 15; 33(3):585-93. PMID: 7558947.
    Citations: 20     Fields:    Translation:Humans
  115. H. Willers, H.-P. Beck Bornholdt. Origins of radiotherapy and radiobiology: „The R’s of radiotherapy“. Radiation Research 1895-1995. Congress Proceedings. 10th International Congress of Radiation Research. 1995; 1:P1631.
  116. H. Willers, H.-P. Beck-Bornholdt. Origins of radiotherapy and radiobiology: fractionation and overall treatment time. Radiotherapy & Oncology. 13th Annual Meeting of ESTRO. 1994; 32:S14.
  117. Henning Willers. The influence of the time factor on the results of x-ray therapy of malignant tumors. 1994.
  118. H. Willers. Dose-rate effects in brachytherapy: The radiobiological basis. Brachytherapy State of the Art in Germany. Proceedings of the 2nd German Brachytherapy Conference. 1994; 1-15.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Willers's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (328)
Explore
_
Co-Authors (93)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.